Reimbursement Review Reports


( Last Updated : April 2, 2015)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Colorectal Cancer In Progress
Unituxin dinutuximab Neuroblastoma Reimburse with clinical criteria and/or conditions Completed
TBC filgrastim Cancelled
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Twynsta Telmisartan / Amlodipine Hypertension Cancelled
Onivyde Nanoliposomal Irinotecan Cancelled
TBD Trastuzumab Cancelled
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled